The vaccine money is in—and it’s pretty good.Pfizer reported revenue of $3.5 billion from its vaccine in the first quarter of 2021. Moderna sold $1.7 billion worth of vaccines in the same period, turning a profit for the first time in the company’s history. BioNTech, which is making the vaccine in partnership with Pfizer, expects $15 billion in vaccine sales this year (with an expected profit above 25%).AstraZeneca and Johnson & Johnson, meanwhile, are providing the shots on a not-for-profit basis. But they have expressed the intention of revising up the cost of their vaccine once the pandemic phase of Covid-19 is over. Their first quarter revenue—they posted $275 million and $100 million re
Hence then, the article about investors are starting to appreciate the business potential of vaccines was published today ( ) and is available onQuartz ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Investors are starting to appreciate the business potential of vaccines )